IL6 and breast cancer: Increased secretion of IL-8 and IL-6 promotes the expression of BC resistance protein (BRCP) by activating the AKT and STAT3 signaling pathways, respectively, which induce doxorubicin treatment resistance by accelerating efflux from BC cells.